<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.82043</article-id><article-id pub-id-type="publisher-id">ACM-24606</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180200000_96360476.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  DCD肝移植供肝质量评估进展文献综述
  The Literature Review of Progress in Quality Assessment for Donation-after-Cardiac-Death Liver Transplantation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>司</surname><given-names>铮先</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>婧星</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>宝志</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>永林</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>升宁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>昆明医科大学第二附属医院肝胆胰二科，云南 昆明</addr-line></aff><aff id="aff2"><addr-line>昆明医科大学附属甘美医院肝胆胰一科，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>15</day><month>03</month><year>2018</year></pub-date><volume>08</volume><issue>02</issue><fpage>253</fpage><lpage>258</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    1963年美国医师Starzl实施了全球首例人体原位肝移植手术，此后随着肝移植外科技术的改进、免疫抑制方案的优化以及移植后病人管理的进步，肝移植成为终末期肝病的最佳治疗手段。然而供肝资源短缺制约了肝移植的进一步发展。近年来心脏死亡器官捐献(DCD)供肝在肝移植手术中的应用，有效扩大了供肝池，并已经得到世界卫生组织认可在全世界范围内实行。DCD供肝作为扩大选择标准的供肝来源，准确评估其质量并确保移植后受体的生存率，是国内外器官移植领域的研究热点。本文就DCD供肝质量评估最新进展作一综述。
    The American surgeon Thomas Starzl performed the first human liver transplantation surgery in human history in 1963. Then improvements in surgical techniques, immunosuppression, and post-transplantation patient care have led to the optimization of liver transplantation outcomes. However, the scarcity of donor liver restricts further development of liver transplantation. In recent years, the use of donation after cardiac death (DCD) liver effectively expands the donor pool and has been accepted by the WHO. There are so many researches focusing on how to effectively assess the quality of DCD liver in order to ensure the survival rate after transplantation. The present essay reviews the latest developments in this field. 
  
 
</p></abstract><kwd-group><kwd>DCD肝移植，DCD供肝质量，脂肪肝，冷–热缺血时间，危险因素, Donation-after-Cardiac-Death Liver Transplantation</kwd><kwd> Quality of DCD Liver</kwd><kwd> Liver Steatosis</kwd><kwd> Cold-Warm Ischemia Time</kwd><kwd> Risk Factors</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>DCD肝移植供肝质量评估进展文献综述<sup> </sup></title><p>司铮先<sup>1</sup>，冯婧星<sup>2</sup>，刘宝志<sup>1</sup>，陈永林<sup>1</sup>，张升宁<sup>1</sup></p><p><sup>1</sup>昆明医科大学附属甘美医院肝胆胰一科，云南 昆明</p><p><sup>2</sup>昆明医科大学第二附属医院肝胆胰二科，云南 昆明</p><p>Email: 1269590445@qq.com</p><p>收稿日期：2018年3月29日；录用日期：2018年4月20日；发布日期：2018年4月27日</p></sec><sec id="s2"><title>摘 要</title><p>1963年美国医师Starzl实施了全球首例人体原位肝移植手术，此后随着肝移植外科技术的改进、免疫抑制方案的优化以及移植后病人管理的进步，肝移植成为终末期肝病的最佳治疗手段。然而供肝资源短缺制约了肝移植的进一步发展。近年来心脏死亡器官捐献(DCD)供肝在肝移植手术中的应用，有效扩大了供肝池，并已经得到世界卫生组织认可在全世界范围内实行。DCD供肝作为扩大选择标准的供肝来源，准确评估其质量并确保移植后受体的生存率，是国内外器官移植领域的研究热点。本文就DCD供肝质量评估最新进展作一综述。</p><p>关键词 :DCD肝移植，DCD供肝质量，脂肪肝，冷–热缺血时间，危险因素</p><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/27-1570530x5_hanspub.png" /> <img src="//html.hanspub.org/file/27-1570530x6_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>肝移植是治疗终末期肝病最有效的手段。随着肝移植外科技术的改进、免疫抑制方案的优化以及移植后病人管理的进步，肝移植的预后得到极大改善 [<xref ref-type="bibr" rid="hanspub.24606-ref1">1</xref>] ，肝移植术后受体生存率显著提高，术后1年的受体存活率为80%~90%，术后10年的受体存活率为70%~80% [<xref ref-type="bibr" rid="hanspub.24606-ref2">2</xref>] 。但近年来脑死亡器官捐献供肝和活体供肝数量的短缺，严重影响了肝移植的进一步发展，使得边缘性心脏死亡器官捐献供肝逐渐被接受并发展为一个重要的供体来源，目前已经得到世界卫生组织认可并在全世界范围内实行 [<xref ref-type="bibr" rid="hanspub.24606-ref2">2</xref>] 。使用DCD供肝进行肝移植已被证明可能增加原发性移植物无功能、胆道系统并发症及再次肝移植的风险 [<xref ref-type="bibr" rid="hanspub.24606-ref3">3</xref>] 。脂肪肝供肝、冷–热缺血时间、高龄、高钠血症、肝炎病毒标志物阳性、肿瘤病史、血管活性药物的使用及重症监护病房(ICU)住院时间是目前较为公认的DCD供肝评估危险因素，与肝移植术后并发症和死亡率密切相关。</p></sec><sec id="s4"><title>2. DCD供肝质量评估</title><sec id="s4_1"><title>2.1. 脂肪肝供肝</title><p>有报道指出约9%~26%的供肝为脂肪肝 [<xref ref-type="bibr" rid="hanspub.24606-ref4">4</xref>] 。随着供者年龄上限的提高和人群肥胖的流行，可以预见脂肪肝供肝在DCD供肝中的比例会进一步增加。这意味着脂肪肝供肝将成为一个巨大的潜在供肝池，使脂肪肝的潜在使用价值逐渐成为肝移植领域的一个研究热点。</p><p>脂肪肝指肝脏脂质沉积超过肝脏湿重的5%，主要表现为甘油三酯的堆积 [<xref ref-type="bibr" rid="hanspub.24606-ref5">5</xref>] ，由于严重的线粒体损伤、能量代谢损害以及氧化应激反应的增强导致其对缺血–再灌注损伤的耐受性较差 [<xref ref-type="bibr" rid="hanspub.24606-ref6">6</xref>] 。脂肪肝有两种病理形式：小泡性脂肪变性和大泡性脂肪变性，通常二者同时存在。有研究证实肝细胞小泡性脂肪变性不趋于导致肝移植的不良预后，不会影响肝移植的最终结果 [<xref ref-type="bibr" rid="hanspub.24606-ref7">7</xref>] 。对于大泡性脂肪变性，一般将其严重程度按照镜检下单位面积可见的大泡性脂肪变性细胞比例分为3级：轻度 &lt; 30%；中度30%~60%；重度 &gt; 60% [<xref ref-type="bibr" rid="hanspub.24606-ref8">8</xref>] 。目前相关研究显示，轻度脂肪变性供肝对移植后肝功能的不利影响不明显，与无脂肪变性供肝结果类似，可以安全用于肝移植手术 [<xref ref-type="bibr" rid="hanspub.24606-ref8">8</xref>] 。中、重度脂肪变性供肝的临床应用结果文献报道存在差异。Adam等 [<xref ref-type="bibr" rid="hanspub.24606-ref9">9</xref>] 统计供肝原发性移植物无功能(PNF)发生率，中度和重度脂肪肝则分别为25%和57%。Spitzer等 [<xref ref-type="bibr" rid="hanspub.24606-ref10">10</xref>] 报道5051例肝移植的患者，研究表明存在超过30%的中重度大泡型脂肪变性被认为是一个独立的风险因素，1年移植存活率明显下降。但也有不同报道，Fishbein等 [<xref ref-type="bibr" rid="hanspub.24606-ref11">11</xref>] 分析40例中度脂肪变性供肝受者的数据，发现其1年存活率及移植物存活率与无脂肪变性供肝患者一致。综合分析，中度大泡性脂肪变性的肝脏可以在紧急情况下及严格限制其他危险因素的情况下有选择性的使用 [<xref ref-type="bibr" rid="hanspub.24606-ref12">12</xref>] ；重度脂肪变性供肝是移植后肝功能衰竭的显著高危因素，会明显增加移植肝原发性无功能的风险，因此经常禁用于移植，除非是在紧急情况下作为过渡性供肝 [<xref ref-type="bibr" rid="hanspub.24606-ref13">13</xref>] 。</p></sec><sec id="s4_2"><title>2.2. 冷–热缺血时间</title><p>热缺血时间指从供体血液循环停止或局部血供终止到冷灌注开始的时间。目前热缺血时间界定为：当供者动脉压 &lt; 50 mmHg (1 mmHg = 0.133 kPa)和(或)氧饱和度 &lt; 70%开始即为热缺血，直至进行冷灌注结束热缺血时间 [<xref ref-type="bibr" rid="hanspub.24606-ref14">14</xref>] 。在DCD供肝获取过程中，供者死亡被定义为不可逆转的心肺功能停止。因此DCD供肝必然经历一段低血压、缺氧的灌注过程，由此产生的热缺血损伤是DCD供肝最重要的特点 [<xref ref-type="bibr" rid="hanspub.24606-ref14">14</xref>] 。Lee等 [<xref ref-type="bibr" rid="hanspub.24606-ref15">15</xref>] 研究证实，供肝热缺血时间&gt;15 min是肝移植预后不良的高危因素。但单以时间长短来评估热缺血损伤对DCD供肝质量的影响存在局限性。Abt [<xref ref-type="bibr" rid="hanspub.24606-ref16">16</xref>] 等的用新的方法回顾性分析心脏死亡器官捐献供肝热缺血过程中血流动力学改变的特点与移植肝存活率之间的关系，发现生命支持撤除后10 min内动脉压变化率与移植物存活率密切相关，但并不呈线性相关，且没有发现具体高位临界点。该研究提示需要发现新的评估参数来反映这一过程。相比之下，脑死亡供者没有热缺血时间，肝移植术后并发症发生率相对较低。</p><p>冷缺血时间指从供肝冷灌注到移植后血供开放前所间隔的时间，包括器官保存阶段。Yotsuka等 [<xref ref-type="bibr" rid="hanspub.24606-ref17">17</xref>] 认为，冷缺血时间是肝移植术后移植肝存活率、受体存活率、原发性移植物无功能的一个重要预测因子。冷缺血时间 &gt; 8 h是DCD肝移植的高危因素。有报道指出，冷缺血时间 &gt; 6 h后，每增加1 h，移植后肝功能衰竭的发生率增加约8% [<xref ref-type="bibr" rid="hanspub.24606-ref18">18</xref>] 。因此，需要更加优化的器官分配策略来减少冷缺血时间。</p></sec><sec id="s4_3"><title>2.3. 高龄</title><p>随着供体的短缺和人群预期寿命的延长，高龄供肝的应用日益增多。Fernandez-Merino等研究发现，肝移植受体的生存率及移植肝功能与供体年龄呈负相关 [<xref ref-type="bibr" rid="hanspub.24606-ref19">19</xref>] 。Liege大学医院移植中心的一项回顾性研究将70名DCD肝移植供者按年龄分为&lt;55岁、56~69岁和 &gt; 70岁3组，DCD供肝获取均由经验丰富的ICU医师和肝移植团队在手术室共同完成，以保证DCD供者撤除生命支持的过程和供肝冷-热缺血时间基本相同，其比较了肝移植术后1个月、1年和3年生存率，结果发现 &lt; 55岁组与56~69岁组之间并无显著性差异，而 &gt; 70岁组生存率明显低于其他两组 [<xref ref-type="bibr" rid="hanspub.24606-ref20">20</xref>] 。因此，在能够保证供肝冷–热缺血时间较短的情况下，供者年龄 &gt; 50岁不应被列为绝对禁忌。</p></sec><sec id="s4_4"><title>2.4. 肝炎病毒标志物阳性</title><p>肝移植术后受者HBV感染的主要途径是供肝传播，但通过严格选择受体，预防性抗病毒治疗以及乙肝免疫球蛋白的合理应用，HBV阳性或者既往有HBV暴露史的DCD供肝仍可以被使用 [<xref ref-type="bibr" rid="hanspub.24606-ref21">21</xref>] 。Testa等 [<xref ref-type="bibr" rid="hanspub.24606-ref22">22</xref>] 的研究明确了来自丙型肝炎病毒(HCV)感染者的器官用于移植是相对安全的。对于肝炎病毒感染活动期和已经发生肝炎病毒相关肝纤维化的病毒阳性DCD供肝是不应使用的。另外，在使用肝炎病毒阳性DCD供肝前，必须进行供肝病理活检。</p></sec><sec id="s4_5"><title>2.5. 高钠血症</title><p>高钠血症会影响移植器官功能，增加移植后肝功能衰竭风险，其作用机制可能与高钠血症造成的细胞肿胀、渗透压增高和再灌注损伤有关。心脏死亡器官捐献供者高钠血症(血清钠 &gt; 155 mmol/L)是影响肝移植预后的重要因素 [<xref ref-type="bibr" rid="hanspub.24606-ref23">23</xref>] 。Chang等设计试验，采用5%葡萄糖液行肠系膜下静脉输注降低DCD供者血钠水平，比较发现输注组17例高钠血症供者供肝移植术后并未发生肝功能衰竭，而未输注组移植后肝功能衰竭的发生率为60% [<xref ref-type="bibr" rid="hanspub.24606-ref24">24</xref>] 。Mangus等 [<xref ref-type="bibr" rid="hanspub.24606-ref25">25</xref>] 认为，术前积极将供者血钠纠正至155 mmoL/L以下对于移植后受者肝功能恢复非常有益。尽管不拒绝高血钠的供者肝脏，但是在供者情况允许的情况下，我们应该尽量保持血钠低于155 mmol/L。DCD供者高钠血症是移植后肝功能不良的危险因素，但通过有效地纠正血钠浓度，这种不良影响可以减小。</p></sec><sec id="s4_6"><title>2.6. 肿瘤病史</title><p>评估有肿瘤病史的供者需考虑其无瘤存活期，但肿瘤复发具有不可预测性。有研究指出，黑色素瘤、绒毛膜癌、淋巴瘤、乳腺癌、肺癌、肾癌及结肠癌在供、受者之间具有高传播风险，有以上肿瘤病史患者不应该作为肝移植供者 [<xref ref-type="bibr" rid="hanspub.24606-ref26">26</xref>] 。根据美国器官资源共享网络数据，约有2.7%的死亡捐献供者有肿瘤病史，2000年至2005年间，共计891例供肝是来自有肿瘤病史的供者并进行了肝移植手术；供者肿瘤类型排在前3位的分别为非黑色素皮肤瘤、中枢神经系统肿瘤和宫颈肿瘤；仅发生2例由供肝转移的致命性肿瘤，其余受者均未发现肿瘤活跃生长和远处转移的证据 [<xref ref-type="bibr" rid="hanspub.24606-ref27">27</xref>] 。使用有肿瘤病史的DCD供者供肝需谨慎，此类供肝评估依赖于具体患者及特定情况下移植团队的决策分析。</p></sec><sec id="s4_7"><title>2.7. 其他</title><p>需要对DCD供肝进行评估的因素还包括血管活性药物的使用及重症监护病房(ICU)住院时间。通常肝移植供者出现血流动力学不稳定，多巴胺需要量 &gt; 10 &#181;g∙kg<sup>−1</sup>∙min<sup>−</sup><sup>1</sup>或需联合使用升压药，将增加肝移植预后风险 [<xref ref-type="bibr" rid="hanspub.24606-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.24606-ref29">29</xref>] 。ICU住院时间的延长能使肝脏肝糖原降低，导致供肝原发性肝功能障碍，因此时间一般控制在4天之内 [<xref ref-type="bibr" rid="hanspub.24606-ref30">30</xref>] 。有研究 [<xref ref-type="bibr" rid="hanspub.24606-ref31">31</xref>] 表明吲哚菁绿(indocyanine green, ICG)清除实验可预测肝移植术后短期移植物功能，如果吲哚菁绿15 min滞留率小于10%，说明肝脏储备功能良好，作为供肝的成功率较高。</p></sec></sec><sec id="s5"><title>3. 总结与展望</title><p>DCD肝移植是降低终末期肝病患者在移植等待过程中死亡率的有效手段，通过行之有效的DCD供肝质量评估，可以有效规避热缺血损伤带来的风险，获得较好的预后。在尽可能缩短冷–热缺血时间的前提下，脂肪肝、高龄、高钠血症、肝炎病毒感染、特定肿瘤病史、血管活性药物的使用及重症监护病房住院时间等都是DCD供肝质量评估需要综合考虑的因素，但并非绝对禁忌因素。结合各移植中心经验并符合我国实际情况的个体化DCD供肝质量评估体系应逐步建立。在具体实施过程中，DCD供肝质量评估应由移植团队综合考量。同时，更多有意义的参数可以纳入评估过程，以获得更全面的评估结果，提高DCD肝移植的术后生存率，减少术后并发症的发生。</p></sec><sec id="s6"><title>文章引用</title><p>司铮先,冯婧星,刘宝志,陈永林,张升宁. DCD肝移植供肝质量评估进展文献综述The Literature Review of Progress in Quality Assessment for Donation-after-Cardiac-Death Liver Transplantation[J]. 临床医学进展, 2018, 08(02): 253-258. https://doi.org/10.12677/ACM.2018.82043</p></sec><sec id="s7"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.24606-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Saidi, R.F. (2012) Current Status of Liver Transplantation. Archives of Iranian Medicine, 15, 772-776.</mixed-citation></ref><ref id="hanspub.24606-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lacaille, F. (2012) Liver Transplantation and Liver Cell Transplantation. Clinics and Research in Hepatology and Gastroenterology, 36, 304-307. https://doi.org/10.1016/j.clinre.2012.03.029</mixed-citation></ref><ref id="hanspub.24606-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Atria, M., Silva, M.A. and Mirza, D.F. (2008) The Marginal Liver Donor—An Update. Transplant International, 21, 713-724. https://doi.org/10.1111/j.1432-2277.2008.00696.x</mixed-citation></ref><ref id="hanspub.24606-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Nadig, S.N., Bratton, C.F. and Karp, S.J. (2007) Marginal Donors in Liver Transplantation: Expanding the Donor Pool. Journal of Surgical Education, 64, 46-50. https://doi.org/10.1016/j.cursur.2006.08.001</mixed-citation></ref><ref id="hanspub.24606-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sherlock, S. (1983) Acute Fatty Liver of Pregnancy and the Microvesicular Fat Diseases. Gut, 24, 265-269.  
https://doi.org/10.1136/gut.24.4.265</mixed-citation></ref><ref id="hanspub.24606-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Selzner, M. and Clavien, P.A. (2001) Fatty Liver in Liver Transplanta-tion and Surgery. Seminars in Liver Disease, 21, 105-114. https://doi.org/10.1055/s-2001-12933</mixed-citation></ref><ref id="hanspub.24606-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Briceno, J., Solórzano, G. and Pera, C. (2000) A Proposal for Scoring Marginal Liver Grafts. Transplant International, 13, S249-S252. https://doi.org/10.1111/j.1432-2277.2000.tb02029.x</mixed-citation></ref><ref id="hanspub.24606-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Imber, C.J., St. Peter, S.D., Handa, A., et al. (2002) Hepatic Steatosis and Its Relationship to Transplantation. Liver Transplantation, 8, 415-423. https://doi.org/10.1053/jlts.2002.32275</mixed-citation></ref><ref id="hanspub.24606-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Adam, R., Reynes, M., Johann, M., et al. (1991) The Outcome of Steatotic Grafts in Liver Transplantation. Transplantation Proceedings, 23, 1538-1540.</mixed-citation></ref><ref id="hanspub.24606-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Spitzer, A.L., Lao, O.B., Dick, A.A., et al. (2010) The Biopsied Donor Liver, Incorporating Macrosteatosis into High-Risk Donor Assessment. Liver Transplantation, 16, 874-884. https://doi.org/10.1002/lt.22085</mixed-citation></ref><ref id="hanspub.24606-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Fishbein, T.M., Fiel, M.I., Emre, S., et al. (1997) Use of Livers with Microvessicular Fat Safely Expands the Donor Pool. Transplantation, 64, 248-251. https://doi.org/10.1097/00007890-199707270-00012</mixed-citation></ref><ref id="hanspub.24606-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Strasberg, S.M., Howard, T.K., Molmenti, E.P., et al. (1994) Selecting the Donor Liver: Risk Factors for Poor Function after Orthotopic Liver Transplantation. Hepatology, 20, 829-838. https://doi.org/10.1002/hep.1840200410</mixed-citation></ref><ref id="hanspub.24606-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Loinaz, C. and Gonzlez, E.M. (2000) Marginal Donors in Liver Transplantation. Hepatogastroenterology, 47, 256-263.</mixed-citation></ref><ref id="hanspub.24606-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Perera, M.T. and Bramhall, S.R. (2011) Current Status and Recent Advances of Liver Transplantation from Donation after Cardiac Death. World Journal of Gastrointestinal Surgery, 3, 167-176. https://doi.org/10.4240/wjgs.v3.i11.167</mixed-citation></ref><ref id="hanspub.24606-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lee, K.W., Simpkins, C.E., Montgomery, R.A., et al. (2006) Factors Affecting Graft Survival after Liver Transplantation from Donation after Car-diac Death Donors. Transplantation, 82, 1683-1688.  
https://doi.org/10.1097/01.tp.0000250936.73034.98</mixed-citation></ref><ref id="hanspub.24606-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Abt, P.L., Praestgaard, J., West, S., et al. (2014) Donor Hemodynamic Profile Presages Graft Survival in Donation after Cardiac Death Liver Transplantation. Liver Trans-plantation, 20, 165-172. https://doi.org/10.1002/lt.23777</mixed-citation></ref><ref id="hanspub.24606-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Totsuka, E., Fung, J., Lee, M., Ishi, T., Umehara, M., et al. (2002) Influence of Cold Ischemia Time and Graft Transport Distance on Postoperative Outcome in Human Liver Transplantation. Surgery Today, 32, 792-799.  
https://doi.org/10.1007/s005950200152</mixed-citation></ref><ref id="hanspub.24606-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Nguyen, J.H., Bonatti, H., Dickson, R.C., et al. (2009) Long-Term Outcomes of Donation after Cardiac Death Liver Allografts from a Single Center. Clinical Transplantation, 23, 168-173.  
https://doi.org/10.1111/j.1399-0012.2009.00968.x</mixed-citation></ref><ref id="hanspub.24606-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Fernandez-Merino, F.J., Nuno-Garza, J., Lopez-Hervas, P., et al. (2003) Donor Age as a Risk Factor for Patient Survival in the Liver Transplant. Transplantation Proceedings, 35, 1795-1797.  
https://doi.org/10.1016/S0041-1345(03)00594-3</mixed-citation></ref><ref id="hanspub.24606-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Detry, O., Derover, A., Meurisse, N., et al. (2014) Donor Age as a Risk Factor in Donation after Circulatory Death Liver Transplantation in a Controlled Withdrawal Protocol Programme. British Journal of Surgery, 101, 784-792.  
https://doi.org/10.1002/bjs.9488</mixed-citation></ref><ref id="hanspub.24606-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Loggi, E., Micco, L., Ercolani, G., et al. (2012) Liver Transplantation from Hepatitis B Surface Antigen Positive Donors: A Safe Way to Expand the Donor Pool. Journal of Hepatology, 56, 579-585.  
https://doi.org/10.1016/j.jhep.2011.09.016</mixed-citation></ref><ref id="hanspub.24606-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Testa, G., Goldstein, R.M., Netto, G., et al. (1998) Long-Term Outcome of Patients Transplanted with Livers from Hepatitis C-Positive Donors. Transplantation, 65, 925-929. https://doi.org/10.1097/00007890-199804150-00011</mixed-citation></ref><ref id="hanspub.24606-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Briceno, J., Marchal, T., Padillo, J., et al. (2002) In-fluence of Marginal Donors on Liver Preservation Injury. Transplantation, 74, 522-526. https://doi.org/10.1097/00007890-200208270-00015</mixed-citation></ref><ref id="hanspub.24606-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Saab, S., Chang, A.J., Comulada, S., et al. (2003) Outcomes of Hepatitis C and Hepatitis B Core Antibody-Positive Grafts in Orthotopic Liver Transplantation. Liver Transplantation, 9, 1053-1061.  
https://doi.org/10.1053/jlts.2003.50208</mixed-citation></ref><ref id="hanspub.24606-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Mangus, R.S., Fridell, J.A., Vianna, R.M., et al. (2010) Severe Hy-pernatremia in Deceased Liver Donors Doas Not Impact Earl Transplant Outcome. Transplantation, 90, 438-443. https://doi.org/10.1097/TP.0b013e3181e764c0</mixed-citation></ref><ref id="hanspub.24606-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">刘现忠, 王轩. 边缘性供肝对肝移植术后肝功能影响及对策[J]. 中国普通外科杂志, 2010, 19(7): 809-812.</mixed-citation></ref><ref id="hanspub.24606-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Kauffman, H.M., Cherikh, W.S., McBride, M.A., et al. (2007) Deceased Donors with a Past History of Malignancy: An Organ Procurement and Transplantation Network/United Network for Organ Sharing Update. Transplantation, 84, 272-274. https://doi.org/10.1097/01.tp.0000267919.93425.fb</mixed-citation></ref><ref id="hanspub.24606-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Goldaracena, N., Qui onez, E., M dez, P., et al. (2012) Extremely Marginal Liver Grafts from Deceased Donors Have Outcome Similar to Ideal Grafts. Transplantation Pro-ceedings, 44, 2219-2222.  
https://doi.org/10.1016/j.transproceed.2012.07.113</mixed-citation></ref><ref id="hanspub.24606-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Cameron, A. and Busuttil, R.W. (2005) AASLD/ILTS Transplant Course: Is There an Extended Donor Suitable for Everyone? Liver Transplantation, 11, S2-S5. https://doi.org/10.1002/lt.20596</mixed-citation></ref><ref id="hanspub.24606-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Adam, R., Reynes, M., Bao, Y., et al. (1993) Impact of Glycogen Content of the Donor Liver in Clinical Liver Transplantation. Transplantation Proceedings, 25, 1536-1537.</mixed-citation></ref><ref id="hanspub.24606-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Olmedilla, L., Lisbona, C.J., Pérez-Peña, J.M., et al. (2016) Early Measurement of Indocyanine Green C1earance Accurately Predicts Short-Term Outcomes after Liver Transplantation. Transplantation, 100, 613-620.  
https://doi.org/10.1097/TP.0000000000000980</mixed-citation></ref></ref-list></back></article>